Barinthus Biotherapeutics plc. - American Depositary Shares, each representing one ordinary share (BRNS)

CUSIP: 91864C107

Q2 2022 13F Holders as of 30 Jun 2022

Security type / class
Equity / American Depositary Shares, each representing one ordinary share
Total 13F shares
6,298,127
Total 13F value
$27,536,000
Holder snapshot 6 signals
Share change
+1,670,756
SEC-reported price per share
$4.45
Number of holders
12
Value change
+$7,434,957
Number of buys
3
Number of sells
3
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
40,291,821

Security key

91864C107

Report period

Q2 2022

Institutions

12

Top holders

10

BRNS full security history Ownership snapshot Full 13F holder table Newer quarter: Q3 2022 Previous quarter: Q1 2022 Barinthus Biotherapeutics plc. SEC filings Barinthus Biotherapeutics plc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of BRNS - Barinthus Biotherapeutics plc. - American Depositary Shares, each representing one ordinary share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Alphabet Inc.
Disclosed value leader
Alphabet Inc.
Comparable rows
10/11
Latest evidence
31 Mar 2022
13F 3/4/5 Lead comparable stake: 3.8% 1 rows are not safely comparable across share classes. Showing 1-6 of 11 holder rows.

Quick read

Alphabet Inc. leads the comparable SEC ownership view at 3.8%.

10 of 11 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Alphabet Inc.'s linked filing trail.
Comparable ownership Top 5
Alphabet Inc. 3.8%
M&G INVESTMENT MANAGEMENT LTD 2.7%
DC Funds, LP 1.6%
Liontrust Investment Partners LLP 1.5%
BlueCrest Capital Management Ltd 1.3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 11 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Alphabet Inc.
13F
Company
13F
3.8%
$7,871,000
1,513,644 shares
 — 31 Mar 2022
M&G INVESTMENT MANAGEMENT LTD
13F
Company
13F
2.7%
$5,443,000
1,088,597 shares
 — 31 Mar 2022
DC Funds, LP
13F
Company
13F
1.6%
$3,339,000
642,204 shares
 — 31 Mar 2022
Liontrust Investment Partners LLP
13F
Company
13F
1.5%
$3,120,000
600,000 shares
 — 31 Mar 2022
BlueCrest Capital Management Ltd
13F
Company
13F
1.3%
$2,822,000
542,673 shares
 — 31 Mar 2022
Johns Hopkins University
13F
Company
13F
0.27%
$561,000
107,968 shares
 — 31 Mar 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
12
Shares
6,298,127
Rows available
12
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2022 vs Q1 2022 Across Filers

Q1 2022 holders
10
Q2 2022 holders
12
Holder diff
2
Investor Q1 2022 Shares Q2 2022 Shares Share Diff Share Chg % Q1 2022 value Q2 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .